loading

Recent events

GLuna Shrimp owner Gabriel Luna

AdvertisementX
AdvertisementX

M&A

Aker BioMarine acquires krill-related assets from Acasti Pharma

The $3.1m deal settles Acasti's obligation to Aker BioMarine

By Undercurrent News | Oct. 24, 2023 18:10 BST
Krill by-products. Credit: Aker Biomarine
Related

Aker BioMarine reports strong Q2 revenue growth, yet margins shrink

Aker Biomarine on track for ‘normalized’ fishing year after landing 49,800t krill

Aker BioMarine gets US approval for new krill dietary supplement

Aker Biomarine ready to deploy first-of-its-kind drone in Antarctica

Former American Seafoods investor Coastal Villages involved in Gustafsson’s bid for pollock giant

After delays, California Dungy crab season to open Jan. 5, 2025

Dungeness crab
AdvertisementX

Norwegian biotech company Aker BioMarine announced Tuesday (Oct. 24) that it has acquired all krill-related patents, along with pre-clinical and clinical data, as well as processing equipment, from Canadian firm Acasti Pharma. [...]

Want to keep reading?

Sign up for a trial to have access to our articles!

Fisheries minister survives Canadian cabinet shuffle

ASMI receives additional $8.5m in gov’t funding to pitch Alaska seafood abroad

Questions swirl around Silver Bay's potential MSC nod

US aquaculture sales grew 38% to $1.57bn in latest census

Salmon, other ‘higher fat fish’ now can be labeled ‘healthy’ in US, FDA says

AdvertisementX

Stay on the pulse

Get recommendations, data, editor’s picks, and the latest news from around the seafood world straight to your inbox.

Select your interests

Please select at least one newsletter d indicates our daily newsletters | 2w indicates twice-weekly | All others sent weekly All briefings are sent weekly, unless otherwise indicated
Region
Breaking news
Jobs
Species
Topic

Fill in your details

Please select at least one newsletter!
  • (eg new industry reports, prices data)
  • (eg subscription or report early birds)
  • (eg advertising, trade shows news)
How we handle your data We never share, sell or distribute our subscribers’ data. You may at any time unsubsribe from our newsletters, and request that we erase all information stored about you. Please check our Privacy policy for more details.

We use MailChimp and HubSpot as our email campaign platforms. By subscribing, you agree that the information you provide will be transferred to MailChimp and HubSpot for processing in accordance with their privacy policies (MailChimp privacy policy, HubSpot privacy policy) and terms (MailChimp terms, HubSpot terms).

Thank you. Please check your inbox to confirm your selection and start receiving newsletters.

Cookies on Undercurrent News

We use cookies for performance, security and analytics. To stop seeing this banner click Accept, or select Manage cookies to set your preferences and privacy settings.